信達生物(01801.HK)擬配售5500萬股總籌43億港元 重點投入臨牀研發及全球化佈局
格隆匯6月26日丨信達生物(01801.HK)發佈公告,2025年6月26日(交易時段前),公司與聯席配售代理(即摩根士丹利及高盛)訂立配售協議,據此,公司同意委任聯席配售代理,及聯席配售代理同意作爲配售代理行事,以作爲公司的代理根據配售協議所載的條款並在其條件規限下,促使承配人(否則自行)以配售價購買5500萬股配售股份。
配售股份將根據一般授權予以發行。配售股份的數目相當於本公告日期已發行股份(不包括庫存股份)總數的約3.33%;及完成配售事項後經擴大已發行股份(不包括庫存股份)總數的約3.22%。假設全部配售股份獲悉數配售及認購,則配售事項所得款項總額預期約爲43.098億港元,而所得款項淨額將約爲42.654億港元。本次配售事項所得淨款項將用於:(i)約90%用於推進公司豐厚的臨牀及臨牀前重點創新管線的全球研發,以及用於公司的全球設施設備佈局;及(ii)約10%將用於公司日常運營。
公告表示,錨定“成長爲國際一流的生物製藥企業”的長期願景,公司依託強大的研發平臺與豐厚的創新管線,正步入全球創新的新成長週期。創新管線的全球化佈局已逐步成爲公司潛在重要的增長引擎,並展現出其核心競爭力。公司相信,本次配售事項將更好地支持公司的全球化佈局,並賦予公司在管線開發上更多支持和靈活性。這將有助於充分並加速實現公司豐厚管線的價值潛能,爲公司與股東創造可持續的長期回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.